Rhythm Pharmaceuticals ((RYTM)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway.’ The study aims to evaluate the efficacy of setmelanotide, a drug designed to treat obesity in patients with specific genetic variants affecting the Melanocortin-4 Receptor pathway, including POMC/PCSK1, LEPR, NCOA1(SRC1), and SH2B1. This research is significant as it targets a niche patient population with limited treatment options.
The intervention being tested is setmelanotide, administered via subcutaneous injection, with a placebo used for control. Setmelanotide is intended to address obesity by targeting genetic variants linked to the MC4R pathway.
The study is interventional, with a randomized, parallel assignment model. It employs triple masking, meaning participants, care providers, and investigators are blinded to the treatment allocation. The primary purpose is treatment-focused.
The study began on December 10, 2021, with primary completion expected in the near future. The last update was submitted on August 12, 2025, indicating ongoing progress and adjustments as needed.
This study update could positively influence Rhythm Pharmaceuticals’ stock performance by showcasing their commitment to addressing genetic obesity, potentially boosting investor confidence. As the study progresses, it may also impact the competitive landscape by setting a precedent in personalized obesity treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.